Clinical Trials Browser

Active not recruiting × Fulvestrant × 90 days × Clear all

NCT05307705 2026-04-20

PIKASSO-01

Phase 1 Active not recruiting

Breast Neoplasms

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

Breast Neoplasms

NCT04553133 2026-04-13

PF-07104091 as a Single Agent and in Combination Therapy

Phase 2 Active not recruiting

BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT04650581 2026-04-13

FINER

Phase 3 Active not recruiting

250 enrolled 13 charts

Breast Neoplasms

NCT04524000 2026-04-08

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Phase 2 Active not recruiting

Advanced Breast Cancer

NCT05038735 2026-04-08

EPIK-B5

Phase 3 Active not recruiting

Breast Neoplasms

NCT06764186 2026-04-08

CAPItana

Phase 3 Active not recruiting

Breast Neoplasms

NCT04544189 2026-04-02

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT04851613 2026-04-02

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

Breast Neoplasms

NCT06635447 2026-03-27

CAPItrue

Phase 3 Active not recruiting

Breast Neoplasms, Disease Progression

NCT04576455 2026-03-20

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Phase 2 Active not recruiting

303 enrolled 23 charts

Breast Neoplasms

NCT00099437 2026-03-18

CONFIRM

Phase 3 Active not recruiting

736 enrolled 14 charts

Breast Neoplasms

NCT05654623 2026-03-18

VERITAC-2

Phase 3 Active not recruiting

624 enrolled 17 charts

Breast Neoplasms

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 2 FDA

Breast Neoplasms

NCT07038369 2026-03-17

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Phase 1 Active not recruiting

BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Phase 1/2 Active not recruiting

HER2-positive Metastatic Breast Cancer

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT04572295 2026-03-11

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Phase 1 Active not recruiting

Acrocephalosyndactylia, Breast Neoplasms

NCT03531645 2026-03-05

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

Phase 2 Active not recruiting

Malignant Neoplasms of Female Genital Organs

NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Phase 2 Active not recruiting

Recurrence

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase 2 Active not recruiting

47 enrolled 17 charts

Breast Neoplasms

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2 Active not recruiting

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

Breast Neoplasms, Recurrence

NCT02947685 2026-02-12

PATINA

Phase 3 Active not recruiting

518 enrolled 15 charts

Breast Neoplasms

NCT05501886 2026-02-10

VIKTORIA-1

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT02763566 2026-02-05

MONARCH plus

Phase 3 Active not recruiting

463 enrolled 20 charts

Breast Neoplasms

NCT05646862 2026-02-05

INAVO121

Phase 3 Active not recruiting

Breast Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT04305496 2026-01-29

CAPItello-291

Phase 3 Active not recruiting

818 enrolled 19 charts 2 FDA

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

Breast Neoplasms